Related Experiment Videos
Immune modulation and sepsis
1Department of Anaesthesiology and Intensive Care Therapy, University Hospital of Friedrich Schiller University, Jena, Germany.
Abstract:
The pathogenesis of sepsis involves not only microbial toxins but also activated host inflammatory mediators. Therefore, besides conventional antibiotic or surgical treatment of infection and supportive intensive therapy, modulating host inflammatory mediators as a conjunctive therapeutic option has been explored in the past decade. Although successful in animal models of sepsis, inhibiting host inflammatory response in human sepsis has failed to improve survival or otherwise show efficacy. Studies are needed which better describe the circumstances under which these therapies may ultimately prove successful.
Insights
Modulating the host inflammatory response in sepsis, while effective in animal studies, has not improved survival in humans. Further research is needed to identify conditions where these sepsis therapies might succeed.
Area of Science:
- Sepsis Pathogenesis and Treatment
- Immunology
- Critical Care Medicine
Background:
- Sepsis involves microbial toxins and host inflammatory mediators.
- Conventional sepsis treatment includes antibiotics, surgery, and supportive care.
- Modulating host inflammatory mediators is an explored adjunctive therapy for sepsis.
Purpose of the Study:
- To review the efficacy of modulating host inflammatory mediators in sepsis.
- To understand the discrepancy between animal model success and human trial failures.
- To identify future research directions for immunomodulatory sepsis therapies.
Main Methods:
- Review of existing literature on sepsis pathogenesis and immunomodulation.
- Analysis of clinical trial outcomes for anti-inflammatory sepsis treatments.
- Comparative analysis of animal models versus human sepsis responses.
Main Results:
- Inhibition of host inflammatory response has shown promise in animal sepsis models.
- Clinical trials inhibiting host inflammatory response in human sepsis have failed to demonstrate efficacy.
- A significant gap exists between experimental and clinical outcomes for these therapies.
Conclusions:
- Current immunomodulatory strategies for sepsis have not improved patient survival.
- Further investigation is required to elucidate the specific conditions for successful immunomodulation in human sepsis.
- Future studies should focus on identifying patient subgroups or specific inflammatory pathways that could benefit from targeted modulation.